Non-invasive assessment of liver fibrosis in patients with alcoholic liver disease by R. Lombardi et al.
Non-invasive assessment of liver fibrosis in patients with 
alcoholic liver disease
Rosa Lombardi, Elena Buzzetti, Davide Roccarina, Emmanuel A Tsochatzis
Rosa Lombardi, Elena Buzzetti, Davide Roccarina, 
Emmanuel A Tsochatzis, Sheila Sherlock Liver Unit and UCL 
Institute for Liver and Digestive Health, Royal Free Hospital and 
UCL, London NW3 2QG, United Kingdom
Author contributions: Lombardi R had the primary authorship 
of the manuscript; Buzzetti E and Roccarina D performed the 
literature research and prepared the tables; Tsochatzis EA revised 
the manuscript for important intellectual content; all authors 
approved the manuscript before the final submission.
Conflict-of-interest statement: Nothing to disclose.
Open-Access: This article is an open-access article which was 
selected by an in-house editor and fully peer-reviewed by external 
reviewers. It is distributed in accordance with the Creative 
Commons Attribution Non Commercial (CC BY-NC 4.0) license, 
which permits others to distribute, remix, adapt, build upon this 
work non-commercially, and license their derivative works on 
different terms, provided the original work is properly cited and 
the use is non-commercial. See: http://creativecommons.org/
licenses/by-nc/4.0/
Correspondence to: Emmanuel A Tsochatzis, PhD, Sheila 
Sherlock Liver Unit and UCL Institute for Liver and Digestive 
Health, Royal Free Hospital and UCL, Pond Street, London NW3 
2QG, United Kingdom. e.tsochatzis@ucl.ac.uk
Telephone: +44-207-7940500
Fax: +44-207-4726226
Received: April 21, 2015
Peer-review started: April 23, 2015
First decision: June 2, 2015
Revised: July 30, 2015
Accepted: August 30, 2015
Article in press: August 30, 2015
Published online: October 21, 2015
Abstract
Alcoholic liver disease (ALD) consists of a broad 
spectrum of disorders, ranging from simple steatosis 
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to alcoholic steatohepatitis and cirrhosis. Fatty liver 
develops in more than 90% of heavy drinkers, however 
only 30%-35% of them develop more advanced forms 
of ALD. Therefore, even if the current “gold standard” 
for the assessment of the stage of alcohol-related liver 
injury is histology, liver biopsy is not reasonable in all 
patients who present with ALD. Currently, although 
several non-invasive fibrosis markers have been 
suggested as alternatives to liver biopsy in patients 
with ALD, none has been sufficiently validated. As 
described in other liver disease, the diagnostic accuracy 
of such tests in ALD is acceptable for the diagnosis of 
significant fibrosis or cirrhosis but not for lesser fibrosis 
stages. Existing data suggest that the use of non-
invasive tests could be tailored to first tier screening 
of patients at risk, in order to diagnose early patients 
with progressive liver disease and offer targeted 
interventions for the prevention of decompensation. We 
review these tests and critically appraise the existing 
evidence. 
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Core tip: Although there has been an explosive 
development and validation of non-invasive fibrosis 
tests particularly in viral hepatitis, data on patients 
with alcoholic liver disease are still scarce. We review 
these tests and critically appraise the existing literature. 
Evidence suggests that such tests could be tailored 
to first tier screening of patients at risk, in order to 
diagnose early patients with progressive liver disease 
and offer targeted interventions for the prevention of 
decompensation.
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INTRODUCTION
Chronic liver disease is one of the main causes 
of morbidity and mortality worldwide, as its most 
relevant complications, namely cirrhosis and liver 
cancer, account for approximately 2% and 1.4% of all 
deaths, respectively[1,2]. Excessive alcohol consumption 
is a major risk factor for chronic liver disease in 
industrialized countries, and is the predominant cause 
of liver disease in 48% cases of cirrhosis in the United 
States[3].
Alcoholic liver disease (ALD) is defined by anam­
nestic history of daily alcohol intake of at least 30 g 
and 20 g for men and women respectively, associated 
with evidence of liver injury[1].
ALD consists of a broad spectrum of disorders, 
ranging from simple fatty liver to more severe forms, 
namely alcoholic steatohepatitis (ASH) and cirrhosis, 
leading to life­threatening complications such as 
hepatocellular carcinoma (HCC) and liver failure. Fatty 
liver develops in more than 90% of heavy drinkers, 
however only 30%­35% of them develop more 
advanced forms of ALD. This suggests the role of 
other contributing factors, such as female sex, obesity, 
drinking patterns, dietary factors, cigarette smoking 
and non­sex­linked genetic factors. In particular, 
genetic factors such as the polymorphism of the 
patatin­like phospholipase domain­containing protein 3 
are currently the focus of further research[3]. 
Early detection of cirrhosis is important in patients 
with ALD, as abstinence can prevent the advent of 
complications and improve prognosis[4,5]. In a cohort 
of 466 patients with ALD cirrhosis, 1­year mortality 
was 17% in the absence of baseline complications, 
progressively increasing to 20%, 29% and 64% 
in the presence of variceal bleeding, ascites, and 
encephalopathy, respectively[6]. Abstinence improves 
survival in patients with established ALD; in a study 
including 283 patients with ALD cirrhosis and a 5­year 
follow-up, a significant difference in survival between 
abstainers and drinkers was demonstrated, with 
corresponding rates of 63% and 45% respectively[7]. 
These data were confirmed by Verrill et al[8] in a 7­year 
follow­up of 100 patients with alcoholic cirrhosis.
The current “gold standard” for the assessment 
of alcohol­related liver injury is histology, obtained 
through liver biopsy. The histological examination 
provides information about liver architecture, presence 
and extent of steatosis, necroinflammation and 
fibrosis. Nevertheless, it is an invasive procedure with 
some limitations. Firstly, it is subject to sampling errors 
and intra and inter­observer interpretation variability, 
mainly due to the small portion of liver examined. 
Secondly, it is associated with patient discomfort and a 
small but significant risk of severe complications, such 
as hemobilia or bleeding[9].
Therefore, although liver biopsy remains essential 
in selected cases, there has been a growing interest 
in non­invasive methods for the assessment of liver 
fibrosis. 
LIVER FIBROSIS AND STAGING 
ASSESSMENT
The fibrogenic process is a maladaptive wound-healing 
response to a generic liver injury characterized by 
excessive production and accumulation of collagen 
and other extracellular matrix proteins by activated 
hepatic stellate cells and portal fibroblasts[3,10]. When 
an imbalance between extracellular matrix production 
and degradation occurs, fibrosis progresses[11].
In ALD, fibrosis begins in the perivenular regions 
and extends to portal tracts, leading to the formation 
of central­portal or portal­portal bridging fibrosis. If 
the alcoholic injury persists, fibrosis and hepatocyte 
regeneration result in nodule formation and finally in 
cirrhosis[10].
Histological examination estimates fibrosis by 
using a semi­quantitative “staging” scoring system 
that takes into account both fibrosis and architectural 
changes[12,13]. Currently different histological semi­
quantitative scoring system are available, such as the 
Ishak and METAVIR scores for viral hepatitis or the 
Brunt and Kleiner score for non­alcoholic fatty liver 
disease. These classification systems use numerical 
categorical labels to describe histological features 
such as steatosis or necroinflammation. One of their 
major limitations is the assignment of fixed numerical 
scores to continuous histological variables, so that 
the numbers provide more a descriptive feature 
rather than an actual measurement. Nevertheless, 
there is no direct correlation of these scoring labels 
with the amount of fibrosis[12]. This limitation is 
reflected in the development and evaluation of non­
invasive fibrosis markers, where the continuous value 
provided by the non­invasive fibrosis test is used 
for the diagnosis of the semi­quantitative stage that 
describes both architecture and distribution of fibrosis, 
and thus probably results in a higher number of 
misclassifications (Table 1). 
Recently, a quantitative method of measuring 
fibrous tissue, through digital image analysis of the 
proportion of collagen in liver tissue, namely collagen 
proportionate area (CPA), has been developed[12­14]. 
CPA is a direct measure of the amount of fibrosis in the 
liver and could be better used for the validation of non­
invasive fibrosis markers but also for the evaluation of 
future anti-fibrotic treatment.
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NON-INVASIVE FIBROSIS TESTS
A diversified set of both serum and imaging potential 
markers has been developed for the non­invasive 
assessment of liver fibrosis. Serum biomarkers are 
classed as indirect (class Ⅱ) or direct (class Ⅰ). The 
development of advanced imaging technique has 
led to the availability of additional tools to stage liver 
fibrosis. The advantages of these new methods are 
the widespread availability, the non­invasiveness and 
the high reproducibility. Therefore, when validated as 
sufficiently accurate, they represent a perfect tool for 
risk stratification, staging fibrosis and long-term follow-
up of patients.
serum biomarkers
Class Ⅱ serum biomarkers or indirect fibrosis 
tests: Class Ⅱ biomarkers consist of routinely 
performed serological tests, which evaluate common 
altered liver parameters, such as transaminases, 
platelet count or albumin. They are not surrogate 
markers of matrix turnover or the fibrogenic process 
in the liver, but rather reflect hepatic function or 
inflammation. They are usually combined into score 
systems or panels where other demographic features 
are included, such as presence of diabetes or age, 
in order to better classify fibrosis stages[15­17]. These 
panels have a high and a low cut­off for the diagnosis 
of a specific fibrosis stage, in order to minimize 
the number of false positive and false negative 
respectively. Therefore, a number of patients fall in the 
“indeterminate zone” between the two thresholds, so 
that additional investigations to classify such patients 
are required. 
Class Ⅰ serum biomarkers or direct fibrosis 
tests: Class Ⅰ biomarkers reflect the products 
derived from the turnover of the extracellular matrix 
during the fibrogenic process. During this process, 
there is a consistent increase in the serum levels of 
fibrogenic cytokines (e.g., tumour­growth factor β), 
extracellular matrix components [e.g., hyaluronic acid 
(HA)], degradation products (e.g., procollagen Ⅳ C 
peptide), and enzymes involved in these processes 
(e.g., tissue inhibitor of metalloproteinases TIMP­1)[15]. 
Such biochemical tests are currently performed 
in designated laboratories and are usually part of 
complex panels.
IMAGING TECHNIQUES
Ultrasound, CT and MRI can only detect the pre-
sence of hepatic steatosis or signs of cirrhosis and 
portal hypertension, with little contribution to the 
identification of patients with less advanced stages 
of fibrosis. Therefore, in recent years new imaging 
techniques have been developed in order to overcome 
this limit and emerging data are accumulating, 
particularly in viral hepatitis. The architectural changes 
in the liver driven by inflammation and deposition of 
fibrotic tissue lead to alterations in the microstructure 
reflected by an increase in the liver stiffness. This can 
be measured by using elastography principles, which 
are based on the propagation of a mechanical share 
wave through the liver parenchyma; the propagation 
velocity reflects the liver stiffness. Moreover, MRI 
technique also adapted to assess hepatic fibrosis by 
modifying phase­contrast imaging sequence to detect 
the shear waves within the liver. 
Transient elastography (TE) or FibroScan® (Echosens; 
Paris, France) was the first imaging modality used 
to detect liver fibrosis. It is an ultrasound­based 
technique that uses an ultrasonic transducer probe (5 
MHz), which emits low­frequency vibrations into the 
liver, creating a propagating shear wave. The latter 
is detected by a pulse­echo acquisition, which then 
calculates its velocity. The results are expressed in 
Kilopascals (kPa) and the final value is the mean of 
ten valid measurements. In order to ensure a reliable 
determination of liver stiffness, an interquartile range 
for measurements within 30% and ratio of success 
rate of measurements > 60% are required[18]. Liver 
stiffness is measured in a volume of approximately 1 
cm wide and 4 cm long, corresponding to nearly 1/500 
of the whole liver volume, thereby representing a 
sample 100 times greater than the one obtained from 
a liver biopsy.
The results range from 2.5 to 75 kPa, however a 
validation of exact stiffness cut-offs for specific fibrosis 
stages is still lacking[19]. Liver stiffness cut­offs for 
the diagnosis of extensive fibrosis or cirrhosis could 
be different according to the cause of the underlying 
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Table 1  Non-invasive serum tests for the assessment of liver 
fibrosis and corresponding stages of alcoholic liver disease 
diagnosed
Test Variables ALD stage 
assessed
AST:ALT ratio ALT, AST ≥ F1, F4
HA HA F4
PGA PT, GGT, apolipoprotein-A1 F4
PGAA PT, GGT, apolipoprotein-A1, 
a2-macroglobulin
FibroTest® Haptoglobin, a2-macroglobulin, 
apolipoprotein-A1, bilirubin, 
GGT
≥ F3, F4
FibrometerA® Age, weight, glucose, AST, ALT, 
PLT count, ferritin
≥ F3, F4
FIB-4 Age, AST, ALT, platelet count ≥ F3
Hepascore® Age, sex, bilirubin, GGT, a2-
macroglobulin, HA
≥ F3, F4
APRI AST, platelet count ≥ F2, F4
ELF test™ HA, PIIINP, TIMP-1 ≥ F3, F4
Forns index Age, platelet count, total 
cholesterol, GGT
≥ F3, F4
ALD: Alcoholic liver disease; ALT: Alanine aminotransferase; AST: 
Aspartate aminotransferase; PT: Prothrombin time; GGT: γ-glutamyl 
transpeptidase; PLT: Platelets; PIIINP: Terminal peptide of procollagen Ⅲ; 
TIMP-1: Tissue inhibitor of metalloproteinase 1; HA: Hyaluronic acid.
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selecting the region of interest by using both B­mode 
and SWE images[25,26]. Unlike Fibroscan, there are no 
established quality criteria for measurements using 
ARFI or SSI.
Magnetic resonance elastography (MRE) combines 
images produced by a traditional magnetic resonance 
(MR) system with a modified phase contrast technique 
able to depict the propagation of acoustic shear waves 
generated by a pneumatic driver. Elasticity values are 
expressed in KPa and are obtained as mean values 
measured in a region of interest within the liver[27]. 
This technique is still undergoing validation and is not 
used in routine clinical practice.
NON-INVASIVE ASSESSEMENT OF LIVER 
FIBROSIS IN ALD
Even if data are accumulating on the use of non­
invasive tests for the assessment of liver fibrosis 
in ALD, nevertheless a small number of studies is 
currently available on such patients compared to 
other causes of liver disease. Therefore, although non­
invasive fibrosis tests have greatly reduced the need 
for liver biopsy, particularly in patients with HCV, the 
evidence is still scant in ALD (Table 2).
serum markers
Aspartate aminotransferase (AST)/alanine amino­
transferase (ALT) ratio includes AST and ALT. Values 
> 1, and especially > 2, are highly suggestive of an 
alcoholic aetiology of liver disease or the presence of 
cirrhosis[28,29]. 
The first serum panel used and validated for the 
detection of cirrhosis among drinkers is the PGA index, 
which consists of prothrombin index (PT), gamma 
glutamyl transferase (GGT) and Apolipoprotein A1[30]. 
Subsequently a2 macroglobulin has been added to 
form the PGAA index. PGAA was tested in a cohort 
of 525 alcoholic patients with different histological 
stages of fibrosis and performed better than PGA 
in detecting significant fibrosis or cirrhosis (correct 
classification in 70% of PGAA and 65% of PGA, P < 
0.001). The derived PGAA cut­offs for excluding or 
diagnosing cirrhosis were ≤ 3 and ≥ 9 respectively. 
Moreover, in a sub­analysis of asymptomatic patients (n 
= 316), a PGAA cut­off of 7 had a sensitivity of 89% 
and specificity of 79% for the diagnosis of cirrhosis, 
suggesting a potentially important role in detecting 
early cirrhosis among drinkers[31].
APRI (AST-To-platelet ratio index) includes AST 
and platelet count as variables. It is calculated as (AST/
upper limit of normal range)/platelet count (109/L) X 
100. Wai et al[32] developed this index in a cohort of 
270 HCV mono-infected patients and showed than 
an APRI cut-off of < 1.0 excluded cirrhosis with a 
negative predictive value of 98%, whereas a score > 
2 was predictive of cirrhosis with a positive predictive 
value of 93%. On the other hand, cut­offs of < 0.5 
liver disease, possibly because liver stiffness mainly 
reflects the amount of liver fibrosis without taking into 
consideration its distribution within the liver, which the 
fibrosis staging systems are based on[20]. 
Fibroscan® has important limitations that need to 
be taken into account. Firstly, it is technically difficult in 
patients with visceral obesity, elevated BMI or narrow 
rib interspaces. Secondly, stiffness values are artificially 
increased in the presence of congestive heart failure, 
acute hepatitis, infiltrative liver disease like amyloidosis 
or if the measurement is performed post­prandially. In 
a 5­year prospective study by Castéra et al[21], which 
included 13369 patients, the probability of failure 
and/or unreliable results of Fibroscan® was 18%; this 
failure was independently associated with obesity, in 
particular increased waist circumference, and limited 
operator experience (< 500 examinations performed). 
The rate of unreliable results is not taken into account 
when the accuracy of TE is reported in studies, thereby 
resulting in an overestimation of its performance. A 
new XL probe for obese patients results in different 
stiffness cut­offs than the M probe and is still under­
going validation.
Acoustic radio force impulse (ARFI) evaluates 
the elastic properties of a hepatic region of interest 
while performing a real­time B­mode conventional 
hepatic ultrasonography, so that large blood vessels 
or ribs could be avoided. The elastography system 
is directly integrated on a standard ultrasonography 
device (Acuson 2000/3000 Virtual TouchTM Tissue 
Quantification, Siemens Healthcare, Erlangen, 
Germany) and short acoustic high­intensity impulses 
with a fixed frequency of 2.67 MHz are sent into 
the tissue inducing a tissue displacement and the 
propagation of shear waves away from the region of 
excitation. The propagation velocity of these shear 
waves is expressed in m/s and correlates to the tissue 
stiffness. The tissue displacements are inversely 
proportional to the stiffness of the tissue, so that a 
stiffer region of tissue exhibits smaller displacements 
than a more compliant region[22]. A high correlation 
between ARFI elastography and Fibroscan® in 
staging of liver fibrosis has been demonstrated[23]. 
ARFI performance seems not to be affected by the 
presence of hepatic steatosis, whereas the influence 
of the inflammatory activity in the liver has been 
confirmed[24].
Supersonic Shear Imaging (SSI), also named 
ShearWave™ elastography, is a new technique based 
on the measurement of the velocity of a local shear 
wave through soft tissues. It uses an ultrasound 
transducer (Aixplorer, Supersonic Imagine, Aix­en­
Provence, France), which emits a series of pulse waves 
at increasing depths, using a very wide frequency 
band ranging from 60 to 600 Hz. By generating a real­
time colour mapping of the elasticity of the tissue 
explored coupled with a B­mode image, SSI provides 
a quantitative imaging of the tissue elasticity. The final 
value is the average the measurement obtained by 
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and > 1.5 excluded and confirmed the presence 
of significant fibrosis (METAVIR F2), respectively. 
Conversely, poorer results have been found in patients 
with ALD, probably due to the direct effect of alcohol 
on platelet count and AST[33]. In a cohort of 507 
patients with ALD, APRI values of > 1.5 had sensitivity 
and specificity of 13.2% and 77.6% respectively for 
the detection of significant fibrosis, and 16.9% and 
86.4% respectively for the diagnosis of cirrhosis at a 
cut­off of 2, thus suggesting a limited utility in clinical 
practice[33]. The relatively poor diagnostic performance 
of APRI was confirmed in a comparative study of 
TE and non­invasive serum tests in a cohort of 103 
alcoholic patients. APRI yielded the lowest AUROC at 
0.56, while FibroTest and PGAA had AUROCs of 0.84 
and 0.83 respectively[34].
The Forns index is based on four routine clinical 
variables: age, platelet count, cholesterol levels and 
GGT. It has been developed to predict advanced 
fibrosis in a cohort of 476 chronic C hepatitis 
patients[35]. Both APRI and Forns scores showed low 
performance in detecting both advanced fibrosis and 
cirrhosis in a cohort of 214 patients with ALD, with 
AUROCs of 0.38 and 0.59 for the former and 0.67 and 
0.38 for the latter, respectively[36]. Similarly, in a cohort 
of 49 patients with ALD, TE was significantly better 
for diagnosing advanced fibrosis than APRI and Forns, 
with corresponding AUROCS of 0.766, 0.611 and 
0.648[37].
The performance of single direct serum markers 
has also been studied in patients with ALD. Of them, 
more data is available on HA. In a systematic review 
by Parkes et al[38], there were 15 identified studies 
on HA in ALD, of which only 7 reported cut­offs 
for the identification of severe fibrosis or cirrhosis. 
Nevertheless, the number of participants was small 
(range n = 70­247) and varying cut­offs for the 
diagnosis of cirrhosis were provided (60­300 µg/L). 
Sensitivity and specificity ranged from 87%­100% 
and 60%-89%, while only 4 studies provided AUROC 
values (median 0.79, range 0.69­0.93). Overall, 
HA was better at excluding severe fibrosis/cirrhosis 
rather than confirming it, and better in the detection 
of cirrhosis compared to milder degrees of fibrosis. In 
particular, in the study of Plevris et al[39] including 70 
alcoholic patients, a threshold of HA > 100 µg/L had 
a 89% specificity and 87% sensitivity for diagnosing 
cirrhosis, with the specificity increasing to 96% for cut-
offs of > 300 µg/L, thus reliably ruling out cirrhosis 
despite the small number on patients considered. 
Conversely, Tran et al[40] considered a lower threshold 
of HA (60 µg/L) in 146 heavy drinkers and showed 
a sensitivity of 100% and a specificity of 86% for 
the detection of cirrhosis. These data suggest that 
HA could be used as a screening test in patients 
who abuse alcohol in order to exclude advanced 
liver disease, provided that a standardized cut­off is 
adequately validated. Conversely, Lieber[41] evaluated 
the performance of TIMP1, P3NT and HA among other 
markers, in a cohort of 247 pre­cirrhotic alcoholic 
patients. The study reported poor accuracy of all these 
markers in the prediction of advanced fibrosis, with 
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Table 2  Non-invasive serum tests to diagnose fibrosis in patients with alcoholic liver disease and corresponding diagnostic indexes
Test Cut-offs F3 F4
Sensitivity Specificity AUROC Sensitivity Specificity AUROC
PGA < 2 NA NA   0.84     0%    83% NA
> 9 NA NA NA   86%  100%   0.89
PGAA < 3 NA NA   0.86 NA NA NA
> 12 NA NA NA NA NA   0.83
Hyaluronic acid, µL > 55 83.0%   69% NA NA NA NA
> 60 NA NA NA 100% 60%-86%2 NA
> 100 NA NA NA   89%    87% NA
> 250 NA NA NA 100%    69%   0.78
APRI < 0.5 NA NA NA NA NA NA
> 1.5 13.2% 77.6% 0.43-0.72 NA NA NA
< 1 NA NA NA NA NA NA
> 2   9.4% 96.6% NA 16.9% 86.4% 0.56-0.792
FIB-4 < 1.45 NA NA 0.7 NA NA 0.8
> 3.25 NA NA 0.7 NA NA 0.8
FibroTest® < 0.3 (0.3-1.581) 84.0%   66%   0.79 100%    50%   0.84
> 0.7 (0.7-1.01) 55.0%   93%   0.83   91%    87%   0.94
FibroMeter® NA 91.8% 92.3% 0.82-0.882 91.8% 92.3% 0.85-0.942
ELF test™ < 0.431 93.3% 100%   0.94 93.3%  100%   0.94
> 9.5 74.4% 92.4% NA 74.4% 92.4% NA
Hepascore® NA NA NA 0.76-0.832 NA NA 0.76-0.922
Forns NA NA NA   0.38 NA NA   0.38
1A single cut-off has not been validated; 2A single value has not been proposed. NA: Not available; ALT: Alanine aminotransferase; AST: Aspartate 
aminotransferase; AUROC: Area under receiver operator characteristic curve; GGT: γ-glutamyl transpeptidase; PLT: Platelets; PT: Prothrombin time; 
PIIINP: Terminal peptide of procollagen Ⅲ; TIMP-1: Tissue inhibitor of metalloproteinase 1; APRI: Aspartate aminotransferase to platelets ratio; ELF: 
Enhanced liver fibrosis.
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corresponding AUROCs of 0.68, 0.67 and 0.69. Plasma 
YKL­40 was tested in 146 heavy drinkers and its levels 
increased in parallel with the severity of fibrosis and 
inflammation. Considering a threshold of 330 mcg/L, 
YKL­40 had a sensitivity of 50.8% and a specificity 
of 88.5 for the detection of advanced fibrosis[42]. 
Therefore, direct serum markers in isolation are 
inadequate for the diagnosis of pre­cirrhotic fibrosis 
stages.
A non­commercial panel of indirect and direct non­
invasive markers was recently developed to stratify 
the risk of advanced liver disease and liver­related 
complications in a cohort of 1038 patients with ALD 
in primary care. The panel consisted of HA, P3NP and 
platelet count, and classified patients as high risk (red 
group), intermediate­risk (amber group) and low­
risk (green group). After a mean follow­up of 46 mo, 
no patients in the green group decompensated or 
died, compared to 3.3% and 14% of deaths in the 
amber and red group respectively. The AUROC of this 
panel was 0.78 and 0.81 for diagnosing any degree 
or significant fibrosis respectively. Since the red and 
amber groups had a significant reduction in survival 
compared to the green one, the panel could be used 
as a screening test in primary care to guide further 
secondary care referrals[43].
FibroTest® consists of total bilirubin, haptoglobin, 
GGT, a2 macroglobulin and Apolipoprotein A1. Imber­
Bismut firstly tested its accuracy in 339 HCV-infected 
patients and reported an AUROC of 0.837 for the 
detection of significant fibrosis. In a cohort of 221 
patients with ALD, FibroTest® values were significantly 
different among distinct stages of liver fibrosis (except 
between F0 and F1). In contrast, HA values only 
differed between advanced stages of fibrosis and 
F0­F2. Moreover, for ≥ F2, the AUROCs of FibroTest® 
and HA were 0.84 and 0.79 respectively, while for the 
diagnosis of cirrhosis the corresponding AUROC were 
comparable at 0.95 and 0.93 respectively[44].
HepaScore® combines age, gender, bilirubin, 
GGT, HA, and gamma2­macroglobulin into a score 
with values ranging from 0 to 1. In a cohort of 512 
HCV patients, HepaScore® had acceptable diagnostic 
accuracy both for significant fibrosis (AUROC = 0.81) 
and cirrhosis (AUROC = 0.88)[29,45]. 
The FibroMeter® derives from the combination 
of several serum markers, such as platelet count, 
prothrombin index, transaminases, GGT, α2 macro-
globulin, HA, blood urea, ferritin, age and sex. It 
comprises six different tests, one for traditional 
histological staging and one for fibrosis quantification 
for each of ALD, NAFLD and viral hepatitis, showing 
the highest performance in chronic C hepatitis[46]. 
In a cohort of 478 patients, of which 95 had ALD, 
Fibrometer® showed a better AUROC (0.96) in 
diagnosing F2­F4 fibrosis stage in ALD, compared to 
Forns index, APRI and FibroTest®[47].
In a study by the group that developed FibroTest®, 
its diagnostic accuracy was compared to that of 
FibroMeter® and Hepascore® in 218 patients with 
ALD. Significant correlations between fibrosis stages 
and each serum panel were found with no significant 
differences in their AUROC for the diagnosis of 
advanced fibrosis and cirrhosis, with corresponding 
values of 0.83 and 0.92-0.94. Nevertheless, in the 
multivariate analysis, FibroTest® was the only factor 
independently associated with both advanced fibrosis 
and cirrhosis, whereas Fibrometer® was independently 
associated only with cirrhosis. Interestingly, the 
combination of these indexes did not improve the 
diagnostic performance of FibroTest®. Moreover, all 
three scores were predictors of 5 and 10 year overall 
survival and non liver­related deaths equally well 
correlated with histological semi­quantitative staging. 
Once again, at multivariate analysis only Fibrotest® 
remained an independent prognostic factor of liver­
related mortality[36]. 
ELF™ score was developed by Rosenberg et al[48] 
in 1021 patients with chronic liver disease of mixed 
aetiologies, showing a high accuracy for the detection 
of significant fibrosis. Importantly, it performed well 
in either hepatitis C, NAFLD or ALD; although only 64 
patients had ALD in the initial cohort, the sensitivity 
and specificity for diagnosing significant fibrosis were 
93% and 100% respectively. These promising results 
need further validation in a larger cohort of patients 
with ALD.
All proprietary serum panels will require independent 
validation in ALD by groups not involved in their 
development.
Imaging techniques: Data on transient elastography 
(TE) are limited in patients with ALD compared to 
other aetiologies of liver disease. Mueller has shown 
that the presence of steatohepatitis an/or ongoing 
alcohol abuse can result in falsely elevated stiffness 
measurements and suggested that TE should not be 
performed in patients with AST > 100 IU/L who are 
actively drinking[49,50]. 
Similar to other aetiologies of liver disease, 
there are no validated cut­offs for the diagnosis of 
specific histological stages in patients with ALD. 
Nguyen-Khac[34] studied 103 patients with ALD and 
showed that stiffness cut­off values of 7.8 and 11 
kPa were predictive of ≥ F2 and ≥ F3 respectively, 
with corresponding sensitivity 80% and 86.7% and 
specificity 90.5% and 80.5%, whereas a cut-off of > 
19.5 kPa was suggestive of cirrhosis. Similar results 
were reported in a study of 711 patients with chronic 
liver disease, of whom 89 (12.5%) had ALD, where a 
cut­off value of 17.6 kPa had a sensitivity of 77% and 
a specificity of 97% for the detection of cirrhosis[51]. In 
another cohort of 147 alcoholic patients, the AUROC 
for patients with advanced fibrosis and with cirrhosis 
were 0.94 and 0.87 respectively. Cut­off values of 12.9 
kPa and 22.6 kPa were optimal for the diagnosis of ≥ 
F3 and F4 respectively[52].
A Cochrane meta­analysis retrieved only 7 studies 
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on patients with ALD with a total of 834 patients[50]. 
Although stiffness cut­offs varied among studies and 
were not defined a priori, the most commonly used 
cut­offs for the detection of advanced fibrosis and 
cirrhosis were 9.5 kPa and 12.5 kPa respectively. At 
these values, TE had a sensitivity of 92% and 95%, 
and specificity of 70% and 71% for the diagnosis of 
F3 and F4 respectively. Only one study reported on F1, 
therefore the performance and cut­off values of TE in 
mild disease are yet to be established. The wide range 
of cut-off values for diagnosing specific fibrosis stages 
significantly affected the specificity of TE. Therefore, 
the diagnostic accuracy of TE is lower in ALD than in 
other causes of liver disease, particularly HCV[53]. As 
previously suggested[50], TE was better in ruling out 
rather than confirming advanced fibrosis and cirrhosis, 
with negative likelihood ratios of 0.11 and 0.07 
respectively. Before TE can be used in clinical practice, 
cut-off values need to be sufficiently validated both in 
patients who continue to abuse alcohol and abstainers.
In order to improve the performance of TE, its 
combination with FIB4 has been tested in a cohort of 
418 patients, showing an improvement in the accuracy 
in detecting advanced liver fibrosis compared to the 
performance of each test alone. Indeed, the new score 
had a sensitivity of 92% and a specificity of 78% 
compared to 87% and 76% of TE alone[54]. No further 
data on the combination of non­invasive tests are 
specifically available in ALD.
ARFI has also been studied in patients with ALD. In 
a cohort of 99 alcoholic patients, ARFI was significantly 
better than APRI, with AUROC of 0.875 and 0.893 for 
diagnosing ≥ S3 and S4 stages of the Scheuer scoring 
system. The optimum cut-off values for ARFI were 
1.40 m/s for S3 and 1.65 m/s for S4. Interestingly, 
cut­off values decreased in the presence of normal 
transaminases, suggesting an influence of liver inflam-
mation on ARFI values similar to TE[55].
A recent study by Cassinotto et al[26] compared 
the performance of Fibroscan®, ARFI and SSI in 349 
patients with mixed aetiology of liver disease using 
histology as the gold standard. It demonstrated a 
superior accuracy of SSI for diagnosing significant 
fibrosis (≥ F2) compared to ARFI and for diagnosing 
severe fibrosis (≥ F3) compared to Fibroscan®. 
Although there were patients with ALD included, no 
separate analysis was performed according to the 
aetiology of liver disease. Nevertheless, the comparative 
accuracy of the technique is not expected to differ 
according to the underlying aetiology of liver disease.
Bensamoun et al[56] compared the diagnostic 
accuracy of MRE and Fibrometer® in 90 patients 
with ALD, using TE as the gold standard for fibrosis 
assessment. The analysis revealed that MRE per-
formed well in the diagnosis of ≥ F1, ≥ F3 and F4, 
with corresponding AUROCs of 0.94, 0.98 and 0.99; 
conversely, Fibrometer® could only accurately detect 
cirrhosis (F4) with an AUROC of 0.95, with lower 
values for ≥ F1, ≥ F2 and ≥ F3 respectively (0.63, 
0.69 and 0.83). As TE has a high number of false 
positive reading in patients with ALD, it is difficult to 
interpret the results of this study as liver biopsy was 
not performed. 
CONCLUSION
Currently, although several non­invasive fibrosis 
markers have been suggested as alternatives to 
liver biopsy in patients with ALD, none has been 
sufficiently validated. In contrast to other aetiologies 
of liver disease, most notably HCV, data are scarce 
and derive from small cohorts of patients. Indeed, two 
separate cost­effectiveness analyses of non­invasive 
fibrosis tests in ALD concluded that such tests cannot 
be currently recommended for the investigation and 
management of such patients[57,58]. This was based 
on both the lack of specific treatment for ALD other 
than abstinence and the limited data on the diagnostic 
accuracy of non­invasive fibrosis tests. As described 
in other liver diseases, the diagnostic accuracy of non­
invasive tests in ALD is acceptable for the diagnosis of 
significant fibrosis or cirrhosis but not for lesser fibrosis 
stages.
Simple panels that rely on AST, such as APRI and 
AST/ALT ratio, are of reduced utility in ALD due to 
the higher AST values in such patients that do not 
necessarily correlate with severe fibrosis. Proprietary 
panels such as Fibrotest, Fibrometer and ELF score 
need further validation. HA has been used either alone 
or in non­proprietary panels[43], however the cut­offs 
used for the diagnosis of advanced fibrosis and/or 
cirrhosis vary across studies and therefore cannot be 
applied in everyday clinical practice.
The most widely evaluated non­invasive test is 
Fibroscan, however its specificity is suboptimal and can 
only be used for ruling out the presence of ≥ F3 or 
cirrhosis. Therefore, its use as a community­screening 
tool in patients who abuse alcohol should be further 
explored. Indeed, the use of non­invasive tests could 
be tailored to first tier screening of patients at risk, 
in order to diagnose early patients with progressive 
liver disease and offer targeted interventions for the 
prevention of decompensation.
In conclusion, even though evidence supporting the 
reliability and utility of non­invasive assessment of liver 
fibrosis in ALD is accumulating, sufficient validation of 
these tests is still lacking, whereas their accuracy for 
the detection of earlier stages of fibrosis needs to be 
improved. 
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